Combination of blood group specificity and interleukin 28B gene polymorphism is a simple and reliable predictor of SVR and dynamics of fibrosis in patients with CHC-I receiving AVT with pegylated interferon a-2 and ribavirin ; also , it may be an instrument of selection of patients for interferon-free therapy .